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The article summarizes the current recommendations and knowledge for the treatment of
patients with artificial valves. The attention is focused on antithrombotic therapy after
valve replacement, including possible complications of the treatment, particularly throm-
boembolic and bleeding complications. We review the procedures when the anticoagula-
tion must be interrupted. The possibilities of improving therapy in patients that require
permanent anticoagulation and the outlook for the future are discussed.
& 2013 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp.z o.o. All
rights reserved.
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More than 100 million patients around the world suffer from
valvular heart disease, as the incidence of degenerative valv-
ular heart disease increases with age. At the present time,
each year approximately 300,000 valves are implanted, and a
further increase is expected. In addition, new less invasive
procedures, percutaneous aortic valve implantation—TAVI and
edge to edge mitral repair—Mitra Clip are also being used.
Czech guidelines were published in 2007 and they are
mainly based on the 2007 European Society of Cardiology
(ESC) guidelines and the AHA/ACC guidelines published in
2006. Recently, new guidelines were published by the Eur-
opean Society of Cardiology as well by the American College
of Chest Physicians (ACCP), which include new knowledge
regarding antithrombotic therapy [1–5].
The current guidelines are in agreement in essential areas,
but there are some points in which the European and American
guidelines differ. This is because the recommendations are
primarily based on retrospective and observational trials, as
prospective randomized trials are missing. At the present time,
there is much progress in cardiology in terms of new antith-
rombotic agents. Many questions therefore emerge:1. How to manage antithrombotic therapy in patients with
valvular disease and in patients with artificial valves?2. What situations require dual antithrombotic therapy?3. How to manage complications during antithrombotic
therapy and in case of requirement for discontinuation
of anticoagulation therapy?4. How to manage patients with artificial valves during
pregnancy?5. Is there any place for new antithrombotics in the treat-
ment of valvular heart disease?6. Is it possible to improve therapy in patients who require
permanent anticoagulation therapy?
2. Antithrombotic therapy in patients with
valvular disease and with artificial valves
2.1. Oral anticoagulation therapy with warfarin1. In patients with native diseased valves
(a) always when atrial fibrillation is present
(b) specific situations arise in patients with mitral steno-
sis, where anticoagulation therapy is indicated in the
presence of atrial fibrillation (paroxysmal, persistent or
permanent), further in patients with thromboembolic
complications during sinus rhythm, and if a thrombus
is present in the left atrium. It should be considered in
patients with a severe mitral stenosis, who have sinus
rhythm but significantly dilated left atrium.2. In patients with artificial valves or valve repair:
The individual risk of thromboembolism should be deter-
mined individually before antithrombotic therapy is initiated.
This is based on what type or surgery was performed—valve
replacement or repair, what type of prosthesis was used
(mechanical, biological, homograft, autograft), another
important factor is the location of the prosthesis (mitral,
aortic, tricuspid, pulmonal) [6].
There are no data from randomized trials for initial
anticoagulation treatment, therefore the regimes vary. Based
on observational trials, most of the embolization events
occurred early after the surgery. It is therefore recommended
to initiate anticoagulation as soon as possible after the
surgery, as soon as the risk of bleeding decreases. Warfarin
therapy is initiated 6–24 h after the operation. Unfractionated
heparin or low molecular weight heparin with monitoring of
aPTT and antiXa is administered simultaneously. Low mole-
cular weight heparin is not recommended in obese patients
and in patients with renal failure [7,8].(A) Permanent anticoagulation therapy is indicated in
patients with mechanical prosthesis regardless the type
of prosthesis or the time of implantation. The target INR
range must take into account the individual patient risk
factors and the thrombogenicity of the valve (Table 1)
Conventional categorization of individual types of pros-
thesis differ between the European and American
guidelines, on top of it the American guidelines recom-
mend the use of warfarin with a low dose of ASA in all
patients with mechanical prosthesis, as the risk of
thromboembolic complications and overall mortality
decreases, however there is an increase in bleeding
complications. Therefore this combination is recommended
in the European as well as in our guidelines in only
targeted patients with an increased risk of thromboembo-
lism [1–5].(B) Permanent anticoagulation therapy in patients with bio-
logical valves, after valve repair, or homografts is indi-
cated if the patient has another indication for chronic
anticoagulation, i.e. atrial fibrillation, left ventricular
dysfunction with ejection fraction of less than 30%.(C) The first 2–3 months after the implantation of a biological
prosthesis in mitral position and after mitral valve repair
with the annuloplastic ring. According to the 2007 Czech
guidelines, a 3-month antiaggregation as well as a 3-
month anticoagulation therapy can be used in the case of
aortic bioprosthesis. (The ACTION and ANSWER trials are
currently investigating whether antiaggregation therapy is
sufficient) [9].(D) 6 months after MAZE procedures, the therapy is pro-
longed if atrial fibrillation persists.
Table 1 – Determination of INR levels in mechanical
prosthesis.
Recommended INR
AVR MVR, TVR, PVR
Without risk factors With risk factors
SR FS
LAo50 mm LAZ50 mm
MValve-Gr 0 MValve Gr þ
EF normal EFr30
SEC SEC þ
Thrombogenicity of the valve
Low 2.5 (2.0–3.0) 3,.0 (2.5–3.5)
Intermediate 3.0 (2.5–3.5) 3.5 (3.0–4.0)
High 3.5 (3.0–4.0) 4.0
AVR—aortic valve replacement, MVR—mitral valve replacement,
TVR—tricuspid valve replacement, PVR—pulmonary valve replace-
ment, SR—sinus rhytmus, AF—atrial fibrillation, M Valve—mitral
valve, EF—ejection fraction, SEC—spontaneous echocontrast.
Risk of thromboembolism in different types of prosthesis:
Low risk: Medtronic Hall, St. Jude Medical (without Silzone),
Carbomedics AVR.
Intermediate risk: bi-leaflet valves with insufficient data on
thrombogenicity, Bjork-Shiley.
High risk: Lillehei Kaster, Omniscience, Starr Edwards.
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valvesPermanent antiaggregation therapy (ASA) is recommended after
the discontinuation of anticoagulation therapy in patients with
biological prosthesis in the mitral and tricuspid position as well
as in patients after mitral repair and MAZE procedures. Accord-
ing to the current European guidelines, ASA should also be used
in the first 3 months in patients with aortic bioprosthesis,
however these guidelines do not clearly specify treatment after
the initial 3 month period. In the other guidelines, antiaggrega-
tion therapy is recommended permanently [10,11].
Patients undergoing homograft implantation or aortic
valve preserving surgery should be on ASA treatment for
three months.
Regardless of lack of data in patients undergoing TAVI or
percutaneous edge to edge repair, dual antithrombotic therapy
with ASA and a thienopyridine is given for 3 months, followed
by monotherapy with either ASA or a thienopyridine [1–4].
In patients with atrial fibrillation undergoing TAVI, a
combination of warfarin and aspirin or thienopyridine is
generally used. It is important to consider increased risk of
bleeding in older and high risk patients. There is a lack of
data from randomized trials, but in our clinical practice the
patients usually use dual therapy (warfarin and thienopyr-
idine) for 1 month and then they use warfarin alone.3. Dual antithrombotic therapy in patients
with valvular disease and artificial valves
The combination of warfarin and low-dose ASA (75–100 mg)
should be considered in patients with high risk of throm-
boembolism, namely in patients with thromboembolic com-
plications during effective anticoagulation therapy, patientswith hyper-coagulation conditions or patients with artificial
valves if significant coronary artery disease or significant
atherosclerosis is present.
Triple therapy (warfarin plus antiplatelet therapy) is asso-
ciated with high bleeding risk. Therefore dose of ASA should
be 100 mg daily or less. In addition, dual antithrombotic
therapy with warfarin and clopidogrel (without ASA) is as
effective as triple therapy, but far more safe as shown in the
recently presented WOEST trial [12].
In patients with mechanical prosthesis, the use of drug
eluting stents should be avoided.
If valve surgery is recommended while the patient is on
dual antithrombotic therapy, the surgery should be post-
poned for one year if possible, or a biological valve should
be used [13–15].4. Complications of antithrombotic therapy
The complications include excessive anticoagulation and
bleeding and on the other side thromboembolic events or
valve thrombosis.
4.1. Excessive anticoagulation and bleeding
In warfarin overdose, the risk of bleeding is increased with an
INR level of 44.5, and exponentially increases in INR 46.
Excessive anticoagulation with INR 45 considerably
increases the risk of bleeding, however a quick decrease of
INR increases the risk of thromboembolic complications.
Patients with an INR 46 and clinically suspected bleeding
should be hospitalized and warfarin should be discontinued
temporarily. The INR levels should be monitored daily, as the
INR should decrease gradually. In urgent situations and if
bleeding occurs, fresh frozen plasma ev. Protromplex instead
of vitamin K should be given. Prothrombin factors as well as
higher doses of vitamin K increase the risk of thrombosis of
the valve due to the possibility of hypercoagulation. A small
dose of vitamin K (up to 1 mg) should be safe [10,11].
4.2. Thromboembolic complications and valve thrombosis
Thromboembolic complications including systemic emboli-
zations occur in between 0.7–6% per year and they can occur
even during the recommended anticoagulation scheme. In
case of such complication it is mandatory to locate the source
of the embolization. The most frequent source is the pros-
thesis alone, but other sources (thrombus in left ventricle or
atrium, carotid stenosis etc.) must also be excluded. Apart
from risk factors of thromboembolism (Table 2), triggers of
thromboembolism can also be identified. For example dehy-
dration associated with increased blood viscosity, pulmonary
infection (with the presence of prothrombic mechanisms),
sudden occurrence of atrial fibrillation, a decrease of INR
level below the therapeutic value. If the risk and trigger
factors are treated, an increase of anticoagulation therapy
associated with high bleeding risk can be avoided.
When the risk of thromboembolism cannot be eliminated,
it is recommended to intensify antithrombotic treatment if
possible.
c o r e t v a s a 5 5 ( 2 0 1 3 ) e 1 5 8 – e 1 6 3 e1611.T
C
A
M
D
F
C
S
D
A
C
o
D
S
H
C
H
Mif the INR is 2.0–3.0, target INR level should be increased to
2.5–3.52. if the INR is 2.0–3.5, target INR level should be increased to
3.5–4.53. if the patient is not on ASA treatment, a dose of 75–100 mg
per day should be added4. if the patient is on warfarin and ASA, the dose of ASA
should be increased to 300 mg/day, if higher target INR
does not have sufficient clinical effect5. if the patient is on ASA monotherapy, higher dose (up to
300 mg/day), or 75 mg dose of clopidogrel or warfarin with
target INR between 2.0 and 3.0 should be added.The addition of ASA to anticoagulation therapy is rela-
tively contraindicated in patients with a history of gastro-intestinal bleeding, in patients with difficultly managed
hypertension on combination therapy and in patients with
poorly controlled INR levels (fluctuations in INR, frequent
episodes of high INR levels).
Valve thrombosis is a rare but severe complication. The
obstruction on mechanical valves oscillates approximately
between 0.3–1.3% per year. Non-obstructive valve thrombosis
occurs more frequently in the early postoperative time period
(10% of patients). The morbidity and mortality usually
depends on how fast the diagnosis is made. The death rate
is approximately 10% regardless of the type of treatment.
Making the diagnosis can be challenging due to heteroge-
neous clinical manifestation. Thrombosis on bioprosthetic
valves is less frequent and it also usually occurs in the early
postoperative period, when the endothelization of sutures is
not yet finished. The diagnosis is based on transthoracic
echocardiography and fluoroscopy (in patients with mechan-
ical valves). Transesophageal echocardiography is valuable
for further assessment. Invasive hemodynamic examination
is not frequently needed. The treatment depends on the
clinical condition, location of the prosthesis and extent of
the thrombosis rather than the type of valve (artificial or
biological) [11,16,17].
The therapy includes the following options: optimization
of anticoagulation and antiaggregation therapy, heparin ther-
apy, fibrinolysis or surgical treatment.able 2 – Risk factors of thromboembolism.
onnected with slow blood velocity
trial fibrillation, dilatation of left atrium (450 mm),
itral stenosis
ecreased LV ejection fraction EF o35%,
unctional class NYHA IV
onnected with vessel disease or endothelial dysfunction
ystemic hypertension
iabetes mellitus
ortic and/or carotid atheromatosis
onnected with increased coagulation and/or aggregation
f platelets
iabetes mellitus
moking
yperlipidemia
hronic inflammation/infection, chronic hemolysis
ypercoagulation conditions
alignancyIn obstructive thrombosis, urgent or emergent surgical
treatment of the valve is the first method of choice in patients
in critical condition without severe co-morbidities (operation
mortality in patients with NYHA I-III is about 4% and in
patients with NYHA functional class IV it is approximately
17.5%). There are many types of surgical procedures, varying
from basic thrombectomy to re-implantation of the valve if the
main cause of the thrombosis was thrombogenicity of the
valve. In this case a less thrombogenic valve should be used.
Fibrinolysis can be used in patients in functional class NYHA
III-IV if they have high operative risk or have contraindications
to the surgical procedure. It can also be used in patients with
functional class NYHA II, if the thrombus is small and antic-
oagulation therapy with heparin has failed. In patients treated
by thrombolysis, systemic embolizations occur in approxi-
mately 12% and themortality rates vary around 10%. In case of
haemodynamic instability a short protocol is recommended,
using either intravenous recombinant tissue plasminogen
activator 10mg bolusþ90 mg in 90min with UFH, or strepto-
kinase 1,500,000 U in 60min without UFH. Longer duration of
infusions can be used in stable patients [1].
Fibrinolysis should also be considered in thrombosis of
tricuspid and pulmonary valve prosthesis as the risk of
thromboembolism is lower. Fibrinolysis is less effective in
thrombosis of mitral prosthesis, in case of chronic thrombo-
sis and in the presence of a pannus, that can be difficult to
distinguish from a thrombus echocardiographically.
The diagnosis of non-obstructive thrombosis of an artifi-
cial valve is made by transesophageal echocardiography that
is performed after a thromboembolic event.
The size of the thrombus and the occurrence of a throm-
boembolic event are the key factors for selecting therapy.
Heparin therapy should last for one week, further treat-
ment is based on a follow-up transesophageal echocardio-
graphy exam. In some cases, the increase in the dose of
warfarin with the addition of a low dose of antiaggregation
therapy (ASA 100 mg daily) is sufficient. Surgical therapy is
recommended in thrombi Z10 mm, in non-obstructive
thrombosis complicated by an embolization, or if the throm-
bus remains even after optimal anticoagulation therapy. If
fibrinolysis is used when small thrombi are present, it is
important to consider higher risk of systemic embolization.
Therefore it should be used very cautiously.
4.3. Antithrombotic therapy before dental and surgical
procedures
In patients with a high risk of thrombosis, and in all
mechanical prosthesis, warfarin is discontinued approxi-
mately 5 days before the procedure, and unfractionated
heparin is given when the INR level is below 2. Heparin is
given up to 5–6 h before the procedure and it is restarted as
soon as possible after the procedure. The treatment is
continued until INR is in the therapeutic range. LMWH can
also be used, but in patients in a critical condition, where an
urgent procedure is possible, unfractionated heparin is pre-
ferred. aPTT or ACT should be monitored every 4 h. When
LMWH is used, the last dose is given 12 h before the
procedure and the next dose is given 12 h after the procedure,
after correction of hemostasis. In patients on anticoagulation
Table 3 – Risk of bleeding in individual procedures.
Low risk:
Diagnostic endoscopy, cataract surgery, dermatology surgery, teeth extraction, operation of hernia and scrotum, arthrocentesis, coronary
angiography
High risk:
Large orthopedic operations, abdominal operations, vascular surgery, urological procedures (PE, operation of urinary bladder), thoracic
operations, neurosurgical operations, cardiac operations, operation of tumors, puncture of arteries without the possibility of compression,
biopsies without the possibility of compression, implantation of pacemaker.
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and is preferred over vitamin K [11].
In low bleeding risk procedures or in surgery where
bleeding can be controlled easily such as dental procedures,
discontinuation of antithrombotic therapy is not required
(Table 3).5. Anticoagulation therapy during pregnancy
Pregnancy in patients with mechanical valves is associated
with high risk. There is no ideal anticoagulation treatment.
Warfarin passes through the uteroplacental unit and admin-
istration of higher doses (45 mg) in the 1st trimester causes
spontaneous abortions and embryopathies (mostly between
6th and 12th week of pregnancy). Warfarin is relatively safe to
use during the 2nd and 3rd trimester (according to some
authors in the 1st trimester with the dose up to 5 mg). The
administration of warfarin must be discontinued 2–3 weeks
before delivery (risk of intracerebral bleeding of the fetus
during delivery). Unfractionated heparin does not pass
through the placenta and is therefore safe for the fetus. aPTT
monitoring is needed (2 daily), and the level should be
prolonged 2–3 times. The value of aPTT can be low due to a
higher concentration of fibrinogen and factor VIII during
pregnancy. Low molecular weight heparin can also be used
in the therapeutic dose (2 daily), but the levels of antiXa
must be measured 4–6 h after the morning dose, with the
target levels of 0.7–1.2 u/ml. Unfractionated heparin should
be given intravenously 4–6 h after delivery, aPTT must be
monitored. Warfarin treatment should be restarted after the
bleeding risk ceases. Warfarin is not contraindicated during
breastfeeding [18–20].6. The use of new antithrombotics in patients
with valvular disease
Currently, anticoagulation therapy in patients with valvular
heart disease is limited to oral vitamin K antagonists. The
well-known disadvantages of coumarins limit their clinical
use: a narrow therapeutic window, an unpredictable biologi-
cal response, and numerous interactions with medications
and food impose strict monitoring of the INR. Insufficient
anticoagulant effect may result in thrombosis, whereas over-
dosing is associated with an increased risk of bleeding
complications. At best, the incidence of major bleeds with
coumarins is between 2% and 4% and should be balanced
against the risk of thrombosis. New antithrombotics are notrecommended in the use of valvular heart disease at this
time [1,5,21].7. Possibilities of improving therapy in
patients that require permanent anticoagulation,
an outlook into the future
After valve surgery, 75% of complications are due to bleeding
or thromboembolism. An ideal (absolutely non-thrombo-
genic) mechanical prosthesis is not yet available and the
new promising anticoagulation drugs were not yet tested in
patients with valvular heart disease.
The recent understanding of the importance of cyto-
chrome P450 2C9 (CYP2C9) and vitamin K oxidoreductase
complex 1 (VKORC1) polymorphisms in the individual
response to coumarins opens a perspective for a dosing
algorithm incorporating CYP2C9 and VKORC1 genotyping
that could improve initial warfarin dose selection and reduce
related complications. One possibility of optimization of
therapy is self-monitoring of INR levels, as it unambiguously
aids in improving the quality of anticoagulation and therefore
lowers the risks of anticoagulation therapy. It is unfortu-
nately not very common in our patients. Careful education of
patients is also important [22–24].
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